ALK and non-small cell lung carcinoma: In the KEYNOTE‐024 trial, previously untreated patients with advanced NSCLC, high PD‐L1 expression, and no EGFR or ALK alterations were randomized to receive either pembrolizumab (a programmed cell death protein 1 [PD‐1] inhibitor) or PBC at the investigator's discretion [51].